17 alpha-hydroxylase deficiency overview: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{MJ}} | {{CMG}}; {{AE}} {{MJ}} | ||
==Overview== | ==Overview== | ||
17 alpha-hydroxylase deficiency was first reported by Dr. Edward G. Biglieri, an American [[endocrinologist]], in 1963-1966 following publication of a case report. 17 alpha-hydroxylase deficiency is an uncommon form of [[congenital adrenal hyperplasia]] resulting from a defect in the [[gene]] [[CYP17A1]], which encodes for the enzyme 17 alpha-hydroxylase and 17,20-lyase. 17 alpha-hydroxylase deficiency is transmitted in an autosomal recessive pattern. [[Mineralocorticoid excess]] and lack of [[androgens]] are two main features in this disease. Mutations in the [[CYP17A1]] gene cause 17 alpha-hydroxylase deficiency. This gene is located on [[chromosome 10]]. 17 alpha-hydroxylase deficiency is a rare disease and from 2010, only 130 individuals with severe, confirmed disease had been documented. Worldwide [[incidence]] of 17 alpha-hydroxylase deficiency is low, especially compared with other forms of [[CAH]]. New cases of 17-hydroxylase deficiency continue to be reported. The most potent risk factor in the development of 17 alpha-hydroxylase deficiency is the presence of [[family history]] of 17 alpha-hydroxylase. Symptoms of 17 alpha-hydroxylase deficiency include [[delayed puberty]] and [[primary amenorrhea]]. Patients with 17 alpha-hydroxylase deficiency usually appear normal. Physical examination of patients with 17 alpha-hydroxylase deficiency is usually remarkable for [[gynaecomastia]], [[hypertension]], and [[sexual infantilism]]. Laboratory findings consistent with the diagnosis of 17 alpha-hydroxylase deficiency include increased [[deoxycorticosterone]] and [[corticosterone]] with low [[cortisol]]. The mainstay of therapy for 17 alpha-hydroxylase deficiency is [[glucocorticoid]] therapy. [[Spironolactone]] and [[Estrogen-replacement therapy|estrogen]] also may be used. Affected [[46,XY]] patients require gonadectomy to prevent malignant degeneration of [[testes]]. The reconstruction surgery for [[ambiguous genitalia]] in genetically male patients may be applied. | |||
==Historical Perspective== | ==Historical Perspective== | ||
| Line 15: | Line 16: | ||
17 alpha-hydroxylase deficiency must be differentiated from diseases with [[primary amenorrhea]] and female [[external genitalia]]. Some of these causes include [[pregnancy]], [[androgen insensitivity syndrome]], 3beta-hydroxysteroid dehydrogenase type 2 deficiency, 17-alpha-hydroxylase deficiency, [[gonadal dysgenesis]], [[testicular regression syndrome]], [[LH receptor]] defects, [[5-alpha-reductase type 2 deficiency]], [[mullerian agenesis]], [[primary ovarian insufficiency]], [[hypogonadotropic hypogonadism]] and [[turner syndrome]]. | 17 alpha-hydroxylase deficiency must be differentiated from diseases with [[primary amenorrhea]] and female [[external genitalia]]. Some of these causes include [[pregnancy]], [[androgen insensitivity syndrome]], 3beta-hydroxysteroid dehydrogenase type 2 deficiency, 17-alpha-hydroxylase deficiency, [[gonadal dysgenesis]], [[testicular regression syndrome]], [[LH receptor]] defects, [[5-alpha-reductase type 2 deficiency]], [[mullerian agenesis]], [[primary ovarian insufficiency]], [[hypogonadotropic hypogonadism]] and [[turner syndrome]]. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
17 alpha-hydroxylase deficiency is a rare disease and from 2010, only 130 individuals with severe, confirmed disease had been documented. Worldwide [[incidence]] of 17 alpha-hydroxylase deficiency is low, especially compared with other forms of [[CAH]]. New cases of 17-hydroxylase deficiency continue to be reported. | |||
==Risk Factors== | ==Risk Factors== | ||
The most potent risk factor in the development of 17 alpha-hydroxylase deficiency is the presence of [[family history]] of 17 alpha-hydroxylase. | |||
==Screening== | ==Screening== | ||
There is insufficient evidence to recommend routine screening for 17 alpha-hydroxylase deficiency. | |||
==Natural history, Complications and Prognosis== | ==Natural history, Complications and Prognosis== | ||
If left untreated, patients with 17 alpha-hydroxylase deficiency may progress to develop [[malignant hypertension]]. Common complications of 17 alpha-hydroxylase deficiency include muscle weakness, [[metabolic alkalosis]], and [[infertility]]. Prognosis is generally good with treatment. | |||
==History and Symptoms== | ==History and Symptoms== | ||
Symptoms of 17 alpha-hydroxylase deficiency include [[delayed puberty]] and [[primary amenorrhea]]. | |||
==Physical Examination== | ==Physical Examination== | ||
Patients with 17 alpha-hydroxylase deficiency usually appear normal. Physical examination of patients with 17 alpha-hydroxylase deficiency is usually remarkable for [[gynaecomastia]], [[hypertension]], and [[sexual infantilism]]. | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
Laboratory findings consistent with the diagnosis of 17 alpha-hydroxylase deficiency include increased [[deoxycorticosterone]] and [[corticosterone]] with low [[cortisol]]. | |||
==CT== | ==CT== | ||
On abdominal [[CT scan]], 17 alpha-hydroxylase deficiency is characterized by bilateral symmetric enlargement of the [[adrenal glands]]. | |||
==MRI== | ==MRI== | ||
On abdominal [[MRI]], 17 alpha-hydroxylase deficiency is characterized by bilateral symmetric enlargement of the [[adrenal glands]]. | |||
==Echocardiography or Ultrasound== | ==Echocardiography or Ultrasound== | ||
On [[ultrasound]], 17 alpha-hydroxylase deficiency is characterized by enlarged, wrinkled, and cerebriform [[adrenal glands]]. | |||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
There is no other imaging studies available for the diagnosis of 17 alpha-hydroxylase deficiency. | |||
==Other Diagnostic Studies== | ==Other Diagnostic Studies== | ||
[[Prenatal diagnosis]] may be used in diagnosis of 17 alpha-hydroxylase deficiency. Different tests which may be used are: [[amniotic fluid]] sampling and oligonucleotide [[hybridization]] of [[deoxyribonucleic acid]] ([[DNA]]) obtained from [[Chorionic villus sampling|chorionic villus biopsies]]; and utilize fetal [[DNA]] extracted from maternal blood through noninvasive methods. | |||
==Medical Therapy== | ==Medical Therapy== | ||
The mainstay of therapy for 17 alpha-hydroxylase deficiency is [[glucocorticoid]] therapy. [[Spironolactone]] and [[Estrogen-replacement therapy|estrogen]] also may be used. | |||
==Surgery== | ==Surgery== | ||
Affected [[46,XY]] patients require gonadectomy to prevent malignant degeneration of [[testes]]. The reconstruction surgery for [[ambiguous genitalia]] in genetically male patients may be applied. | |||
==Prevention== | ==Prevention== | ||
[[Prenatal diagnosis]] of 17 alpha-hydroxylase deficiency is conducted to prevent complication of the disease in future life and treated with prenatal [[dexamethasone]] treatment. | |||
==Reference== | ==Reference== | ||
{{Reflist}} | {{Reflist}} | ||
Revision as of 18:10, 7 August 2017
|
17 alpha-hydroxylase deficiency Microchapters |
|
Differentiating 17 alpha-hydroxylase deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17 alpha-hydroxylase deficiency overview On the Web |
|
American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency overview |
|
Risk calculators and risk factors for 17 alpha-hydroxylase deficiency overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
17 alpha-hydroxylase deficiency was first reported by Dr. Edward G. Biglieri, an American endocrinologist, in 1963-1966 following publication of a case report. 17 alpha-hydroxylase deficiency is an uncommon form of congenital adrenal hyperplasia resulting from a defect in the gene CYP17A1, which encodes for the enzyme 17 alpha-hydroxylase and 17,20-lyase. 17 alpha-hydroxylase deficiency is transmitted in an autosomal recessive pattern. Mineralocorticoid excess and lack of androgens are two main features in this disease. Mutations in the CYP17A1 gene cause 17 alpha-hydroxylase deficiency. This gene is located on chromosome 10. 17 alpha-hydroxylase deficiency is a rare disease and from 2010, only 130 individuals with severe, confirmed disease had been documented. Worldwide incidence of 17 alpha-hydroxylase deficiency is low, especially compared with other forms of CAH. New cases of 17-hydroxylase deficiency continue to be reported. The most potent risk factor in the development of 17 alpha-hydroxylase deficiency is the presence of family history of 17 alpha-hydroxylase. Symptoms of 17 alpha-hydroxylase deficiency include delayed puberty and primary amenorrhea. Patients with 17 alpha-hydroxylase deficiency usually appear normal. Physical examination of patients with 17 alpha-hydroxylase deficiency is usually remarkable for gynaecomastia, hypertension, and sexual infantilism. Laboratory findings consistent with the diagnosis of 17 alpha-hydroxylase deficiency include increased deoxycorticosterone and corticosterone with low cortisol. The mainstay of therapy for 17 alpha-hydroxylase deficiency is glucocorticoid therapy. Spironolactone and estrogen also may be used. Affected 46,XY patients require gonadectomy to prevent malignant degeneration of testes. The reconstruction surgery for ambiguous genitalia in genetically male patients may be applied.
Historical Perspective
17 alpha-hydroxylase deficiency was first reported by Dr. Edward G. Biglieri, an American endocrinologist, in 1963-1966 following publication of a case report.
Classification
17 alpha-hydroxylase deficiency may be classified into two types, based on clinical findings: partial form and severe form.
Pathophysiology
17 alpha-hydroxylase deficiency is an uncommon form of congenital adrenal hyperplasia resulting from a defect in the gene CYP17A1, which encodes for the enzyme 17 alpha-hydroxylase and 17,20-lyase. 17 alpha-hydroxylase deficiency is transmitted in an autosomal recessive pattern. Mineralocorticoid excess and lack of androgens are two main features in this disease.
Causes
Mutations in the CYP17A1 gene cause 17 alpha-hydroxylase deficiency. This gene is located on chromosome 10.
Differential Diagnosis
17 alpha-hydroxylase deficiency must be differentiated from diseases with primary amenorrhea and female external genitalia. Some of these causes include pregnancy, androgen insensitivity syndrome, 3beta-hydroxysteroid dehydrogenase type 2 deficiency, 17-alpha-hydroxylase deficiency, gonadal dysgenesis, testicular regression syndrome, LH receptor defects, 5-alpha-reductase type 2 deficiency, mullerian agenesis, primary ovarian insufficiency, hypogonadotropic hypogonadism and turner syndrome.
Epidemiology and Demographics
17 alpha-hydroxylase deficiency is a rare disease and from 2010, only 130 individuals with severe, confirmed disease had been documented. Worldwide incidence of 17 alpha-hydroxylase deficiency is low, especially compared with other forms of CAH. New cases of 17-hydroxylase deficiency continue to be reported.
Risk Factors
The most potent risk factor in the development of 17 alpha-hydroxylase deficiency is the presence of family history of 17 alpha-hydroxylase.
Screening
There is insufficient evidence to recommend routine screening for 17 alpha-hydroxylase deficiency.
Natural history, Complications and Prognosis
If left untreated, patients with 17 alpha-hydroxylase deficiency may progress to develop malignant hypertension. Common complications of 17 alpha-hydroxylase deficiency include muscle weakness, metabolic alkalosis, and infertility. Prognosis is generally good with treatment.
History and Symptoms
Symptoms of 17 alpha-hydroxylase deficiency include delayed puberty and primary amenorrhea.
Physical Examination
Patients with 17 alpha-hydroxylase deficiency usually appear normal. Physical examination of patients with 17 alpha-hydroxylase deficiency is usually remarkable for gynaecomastia, hypertension, and sexual infantilism.
Laboratory Findings
Laboratory findings consistent with the diagnosis of 17 alpha-hydroxylase deficiency include increased deoxycorticosterone and corticosterone with low cortisol.
CT
On abdominal CT scan, 17 alpha-hydroxylase deficiency is characterized by bilateral symmetric enlargement of the adrenal glands.
MRI
On abdominal MRI, 17 alpha-hydroxylase deficiency is characterized by bilateral symmetric enlargement of the adrenal glands.
Echocardiography or Ultrasound
On ultrasound, 17 alpha-hydroxylase deficiency is characterized by enlarged, wrinkled, and cerebriform adrenal glands.
Other Imaging Findings
There is no other imaging studies available for the diagnosis of 17 alpha-hydroxylase deficiency.
Other Diagnostic Studies
Prenatal diagnosis may be used in diagnosis of 17 alpha-hydroxylase deficiency. Different tests which may be used are: amniotic fluid sampling and oligonucleotide hybridization of deoxyribonucleic acid (DNA) obtained from chorionic villus biopsies; and utilize fetal DNA extracted from maternal blood through noninvasive methods.
Medical Therapy
The mainstay of therapy for 17 alpha-hydroxylase deficiency is glucocorticoid therapy. Spironolactone and estrogen also may be used.
Surgery
Affected 46,XY patients require gonadectomy to prevent malignant degeneration of testes. The reconstruction surgery for ambiguous genitalia in genetically male patients may be applied.
Prevention
Prenatal diagnosis of 17 alpha-hydroxylase deficiency is conducted to prevent complication of the disease in future life and treated with prenatal dexamethasone treatment.